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ABSTRACT OF THESIS
DEVELOPMENT AND EVALUATION OF NONRADIOACTIVE METHODS FOR
MONITORING T LYMPHOCYTE RESPONSE TO EQUINE ARTERITIS VIRUS
(EAV) IN HORSES
Target cell lysis is the hallmark of immune effector responses of cytotoxic T lymphocytes
(CTL), natural killer (NK) cells, and monocytes. The most commonly used assay to
measure target cell lysis is the 51Cr release assay and is considered the ‘gold standard’.
However, this assay has many disadvantages that limit its use by most laboratories. Thus,
several alternative assays have been developed. Some of these alternative assays are more
sensitive, easy to perform and do not use radioactive elements.
In this study, four of these assays were evaluated for their ability to detect antigenspecific CTL responses in equine blood. Three long-term equine arteritis virus (EAV)
carrier stallions, two vaccinated stallions and one naïve stallion were included in this study.
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood collected of
these stallions to be used as effector cells. The PBMCs were stimulated with EAV in vitro
for 7-10 days to generate antigen-specific effector cells. The granzyme B assay, the
Carboxyfluorescein succinimidyl ester (CFSE)/7-Aminoactinomycin D (7AAD) assay and
the Lactate dehydrogenase (LDH) assay were performed using these effector cells and
autologous equine dermal cells (isolated from each stallion) as target cells.
The first two assays (i.e., granzyme B and CFSE/7AAD assays) were difficult to
optimize for this study because they work well with non-adherent targets and require
immediate flow cytometry analysis. The LDH assay, however detected CTL lysis in one
of the two vaccinated stallions at day 99 post vaccination and no response was detected in
PBMCs isolated from carrier stallions and control stallion. Based on these findings, the
LDH assay is the most suitable assay since it works well with adherent target cells, it
produces quantitative data, and is ideal for high-throughput screening.
KEYWORDS: Cytotoxic T lymphocyte assays, Lactate dehydrogenase
assay, Equine arteritis virus.
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1.1 Background

CHAPTER 1. INTRODUCTION

Immune defense mechanisms fall into two broad categories: innate immunity and
adaptive immunity.1 Innate immunity is always present and is the first line of defense
against invading microorganisms. Adaptive immunity is also referred to as acquired
immunity because it requires prior exposure to an antigen. Adaptive immunity is further
divided into humoral immunity and cell-mediated immunity. Humoral immunity is
mediated by antibodies produced by B cells and is usually directed at extracellular
organisms. Cell- mediated immunity is mediated by T lymphocytes and is usually directed
at intracellular invaders.1
T lymphocytes recognize antigens through their T cell receptor (TCR), in the form
of short peptides presented on major histocompatibility complex (MHC) by antigen
presenting cells or infected cells.2 T lymphocytes that express CD8 molecules on their
surface are known as CD8+ T lymphocytes. Upon recognition of antigen, CD8+ T
lymphocytes differentiate into cytotoxic T lymphocytes (CTL) which directly kill microbe
infected cells. Another subset of T lymphocytes, the CD4+ T lymphocytes, are very active
at producing cytokines that help B cells make antibodies and activate antigen presenting
cells. Studies in mice and human show that CD4+ T lymphocytes are also required for
generation of functional memory CD8+ T lymphocytes.3
Despite the remarkable sensitivity of the immune system at recognizing and
eliminating infected cells, chronic infections still exist. This is because some microbes have
evolved mechanisms to evade immune system recognition including down regulating
MHC expression,4 antigenic variation,5 molecular piracy 6 and dysregulation of the
1

immune system.7 Hence, there remains a need for novel vaccines that stimulate both
antibody and cellular immune responses. While there are a number of methods available
to measure antibody responses, accurate and reproducible assays for measuring T cell
responses are lacking.8 Furthermore, T cell assays that closely correlate with host
protection are very difficult to develop.8 The chromium release assay has been successfully
used to measure T cell mediated immune response in horses, but this assay uses radioactive
material which limits its use by some laboratories. Here, we evaluated three alternative
methods to identify a CTL response to a virus.
1.2 Rationale for this study
Measuring T cell response provides valuable information that can be used to
develop new vaccines or optimize existing vaccines. Immune system monitoring can also
reveal factors that can limit protective immunity. The aim of this project was to develop
and evaluate T cells assays that could be used in future studies for monitoring T cell
responses to an important viral pathogen of horses, equine arteritis virus (EAV).

2

CHAPTER 2. LITERATURE REVIEW
2.1 Equine arteritis virus (EAV)
EAV is an enveloped, positive sense single stranded RNA virus with a spherical
virion that has a diameter of 40-60nm. The EAV N protein forms the nucleocapsid which
encapsulates the positive sense ssRNA genome of 12.7 kilobases.9-12 The EAV genome is
polycistronic; with two large open reading frames (at 5’ end) that encode the replicase
protein (the nonstructural protein of EAV) and a set of eight open reading frames (2a, 2b,
3, 4, 5a, 6 and 7) located downstream of the genome. The eight open reading frames (ORFs)
encode structural proteins: E, GP2, GP3, GP4, GP5, M and N respectively (Figure 1).9, 1315

Figure 1: Schematic representation of the EAV virion
The GP5 and M are the major envelope proteins while E, GP2, GP3 and GP4 are
minor envelope proteins.14,

16, 17

Translation of the replicase protein yields two large

proteins; EAV replicase polyprotein1a and polyprotein1ab. These polypeptides undergo
posttranslational cleavage by three viral proteases (nsp1, nsp2, and nsp4) encoded by
ORF1a to produce 13 nonstructural proteins (nsp1-nsp6, 7α and 7β, nsp8-nsp12).18-25
3

Comparison of GP5, M and N sequences of EAV from carrier stallions revealed that M and
N proteins are more conserved than GP5. The N protein is the most conserved structural
protein of EAV whereas the GP5 is the most variable structural protein and contains major
neutralizing determinants of EAV. 26-29
2.2 Major structural proteins of EAV
The EAV nucleocapsid (N) protein is a non-glycosylated protein (14kda;110aa)
encoded by ORF 7.30 It is dispensable for genome replication and mRNA synthesis since
these processes have been shown to go on with the N protein trapped in the nucleus.31 In
infected cells, the N protein constitutes 30 to 45% of the protein moiety making it the most
abundant protein.32 It plays an important role in encapsidating the viral genome and in
interacting with envelope proteins during virus assembly. Thus N protein is necessary for
virus assembly and for production of infectious virus particles.33 A 7 year-long comparative
nucleotide sequence analysis of virus isolated from carrier stallion semen showed that
ORF7 is the most conserved gene of EAV.26
The non-glycosylated membrane protein (M) and the large envelope glycoprotein
GP5 are the two major envelope proteins of the virus, and are encoded by ORF 6 and 5,
respectively. The M protein is 16-kDa and 162 amino acid long,30 it is predicted to span
the viral envelope three times with its internal trans-membrane segments, leaving a short
stretch of 10-18aa exposed at the outside of the virion (ectodomain) and an approximately
72-residue buried inside the virion (endodomain).9, 34
The GP5 protein is 42-kDa and 255 amino acids in length.30 It is heterogeneously
glycosylated and has an ectodomain (of 19-116aa), three membrane-spanning domains and
an endodomain of about 64 amino acids. Comparative analysis of deduced amino acid
sequences of the GP5 protein identified three distinct variable regions (V1 [aa 61-121], V2
4

[aa 141-178], and V3 [aa 202-222]), a putative signal sequence (S[aa 1-18]), and four
conserved regions (C1[aa 19-60], C2 [aa 122-140], C3 [aa 179-201], and C4 [aa 223255]).29 The GP5 protein expresses the neutralization determinants of the virus, all located
on the ectodomain of the GP5 protein.35, 36 When expressed individually, GP5 and M
proteins are retained only in the ER. In contrast, when co-expressed, the M protein localizes
both in ER and the Golgi complex and the GP5 protein consistently co-localizes with the
M protein in the Golgi complex showing that their transport is dependent upon the
formation of a GP5/M heterodimer.37
2.3 Equine viral arteritis (EVA)
Majority of EAV infections are subclinical, but occasional sporadic respiratory
disease, sudden death of foals and mild clinical symptoms in adult horses have been
reported.38-41 Abortion in pregnant mares and delivery of weak foals presenting with
interstitial pneumonia are the most important clinical manifestations of EVA.42, 43 EAV is
transmitted through the respiratory route (by aerosolization of respiratory secretions in
acutely infected animals) or the venereal route.

41

Experimental inoculations of horses

reveal that, within a day of infection, the virus invades and replicates in the respiratory
epithelium and alveolar macrophages before spreading to bronchial lymph nodes on day 2.
On day 3, the virus replicates in bronchopulmonary lymph nodes and circulating
monocytes. Viral shedding in nasal secretions typically lasts 7-14 days, although it can
extend to 21days post infection.44 Systemic distribution of the virus is facilitated by
infected monocytes.44, 45 Cell-associated viremia develops within 3 days of infection and
can go on until day 19 post infection. During this period, the virus replicates in
macrophages, vascular smooth muscle cells and endothelial cells causing systemic

5

panvasculitis.46-48 EAV replication in endothelial cells damages the endothelium leading to
increased permeability and recruitment of inflammatory cells to the endothelium.49,

50

Increased vascular permeability and leukocyte infiltration results into edema and
hemorrhage around the vessels. This severe vascular damage will eventually lead to
disseminated vascular coagulation.16, 43
Between 10% and 70% of EAV infected stallions become carriers.51-54 The carrier
state established in the reproductive tract of stallions provides a reservoir of EAV because
carrier stallions can transmit the virus to susceptible mares by natural breeding or by
artificial insemination. These infected mares can in turn disseminate the virus to susceptible
horses.36 Studies done by Little et al, show that the establishment and maintenance of the
carrier state is testosterone dependent, as persistently infected stallions eliminate the virus
after castration and those that receive testosterone after castration, continue to shed the
virus in semen.55 The carrier state can be short-term that lasts for a few weeks after clinical
recovery, intermediate carrier state that lasts for 3 to 7 months, or long-term carrier state
that lasts several years.56, 57 Long-term carrier stallions may spontaneously cease virus
shedding after intervals of 1 to 10 years, with no reversion to the shedding state.57 EAV
has been shown to persist in the ampulla of the stallion reproductive tract .54, 58
Recent studies show that horses can be divided into two groups (i.e. susceptible and
resistant) based on in vitro susceptibility of their CD3+ T lymphocytes to EAV.59,

60

Stallions that possess the susceptible phenotype are at increased risk of becoming longtime carriers whereas stallions lacking this phenotype are less likely to become long-time
carriers. A genome wide association study (GWAS) revealed that the ability of EAV to
infect CD3+ T lymphocytes and establish long-term carrier status in stallions correlated

6

with a region within equine chromosome 11(exon 1) that encodes CXCL16 protein.61
Equine CXCL16 susceptible(CXCL16S) and CXCL16 resistant (CXCL16R) have been
shown to differ at positions 40, 49, 50 and 52. Consequently, the in vitro susceptibly is
associated with CXCL16S while the resistant phenotype is associated with CXCL16R.62
Long term EAV persistence has been associated with downregulation of miRNA (eca-mir128) a putative target of CXCL16 leading to overexpression of this protein.
2.4 Immune response to EAV
EAV has been shown to inhibit type 1 interferon production in endothelial cells.63,
64

In addition, infection of alveolar macrophages and blood derived microphages with

avirulent and virulent strains of EAV showed increased expression of pro-inflammatory
cytokines, and the magnitude of this response was greater in virulent strains than avirulent
strains.65 Humoral immune response to EAV also varies with the infecting strain and
duration of infection. Sera from EAV infected horses recognize M, N, GP5, nsp2, nsp4,
nsp5 and nsp12.66, 67 The GP5 ectodomain contains the four major EAV neutralizing sites,
all located in GP5’s variable region 1 (V1).

35, 36, 68

EAV induces production of Virus

Neutralizing (VN) antibodies within 2 weeks of infection, these antibodies peak at 2-4
months and persist for 3 years or more after that.69-71

30, 72

Complement fixing antibodies

develop 1-2 weeks post infection and peak 2-3 weeks after infection and they disappear by
the eighth month.16,

30, 36

IgM antibodies have been reported as early as 6 Days Post

Infection (DPI), they peak at 10DPI and decline by 21-49 DPI.30 Foals are protected
against EAV infection by passive transfer of VN antibodies in colostrum and these
antibodies persist for 6 months.73, 74 Recently, EAV has been shown to elicit a mucosal
antibody response in the reproductive tract of persistently infected horses. Analysis of
seminal plasm shows the presence of EAV-specific immunoglobulin isotypes IgA, IgG1,
7

IgG3/5, and IgG4/7 with IgG1 and IgG4/7 showing virus-neutralizing activity.75 Also,
significant infiltration of T lymphocytes, macrophages and dendritic cells into the
reproductive tract of carrier horses has been reported.76 However, the role of these cells is
not known since the virus was still persists irrespective of immune cells infiltrating the
reproductive tract.
2.5 Immune response to viruses
2.5.1 Innate immune response to viral infection
Innate immune response uses pattern recognition receptors (PRRs) to detect
specific viral components such as viral RNA or DNA or viral intermediates. Endosomal
Toll like receptors (TLRs) are activated by nucleic acids. These TLRs include: TLR3,
TLR7, TLR8 and TLR9.77 Activation of these receptors induces the production of type 1
interferons and other proinflammatory cytokines by infected cells or immune cells. Type 1
interferons are the principal cytokines involved in antiviral response. These include INFα, INF-β and others.78
2.5.2 Humoral immune response to viral infection
Mucosal immune system acts as the first line of defense to limit respiratory viral
infection. Secreted IgA and IgM are the major neutralizing antibodies on mucosa to prevent
viral entry. During infection with influenza, nasal secretions contain IgA which can
neutralize

hemagglutinin

and

neuraminidase

of

influenza

A

virus

(IAV).

Immunoglobulins: IgG, IgM and IgA are present in mucosal secretions during primary IAV
infection.79 In certain viral infections, serum neutralizing antibodies are associated with
reduced viral replication.80 All clinically protective vaccines depend on the production of
neutralizing antibody response. This is because antibodies not only prevent entry of

8

viruses, but they also facilitate the removal of infected cells.
2.5.3 Innate immunity and antigen presentation
Cells of the innate immune system use pattern recognition receptors (PRRs) to
sense viral pathogens by detecting pathogen-associated molecular patterns (PAMPs) on
viruses. PAMPs are conserved moieties expressed by microbes. Majority of viruses are
sensed via recognition of their nucleic acids which accumulate during replication. Pattern
recognition receptors (PRRs) also respond to signatures such as 5′ triphosphate RNA,
which is not normally found in host RNA but present in viruses.81 Pattern recognition
receptors (PRRs) are germ-line encoded receptors expressed by innate immune cells such
as macrophages, neutrophils and dendritic cells. There are 3 main categories of virus
associated PRRs: Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), and NOD-like
receptors (NLRs).82 Toll-like receptors (TLRs) are in the plasma membrane or endosomal
vesicles.83 Plasma membrane TLRs are usually specific for hydrophobic lipids and proteins
while those found in endosomes detect nucleic acids.81 When viruses enter host cells, they
uncoat their genomes and release viral components into the cytoplasm. These viral
components are detected by retinoic acid-inducible gene I-like receptors (RLRs), the
nucleotide oligomerization domain-like receptors (NLRs) and cytosolic DNA sensors such
as members of the AIM2 family.81, 82, 84
2.5.4 Differentiation of CD4+ T lymphocytes after antigen presentation
At the initial stages of infection, innate immune cells such as APCs sense the
invading virus by engaging PRRs.77,

85, 86

This activates the APCs to upregulate co-

stimulatory molecules (e.g. CD40, CD80:CD86), major histocompatibility (MHC)
molecules and promotes migration of the APCs to draining lymph nodes. Here, the APCs
present virus-derived peptides on MHC class II molecules to naive CD4+T cells and
9

deliver co-stimulatory signals.55 (Figure 2)

Figure 2: Activation of CD4+ T lymphocytes and their effector functions
The naïve CD4+ T cells then undergo clonal expansion and differentiate into
distinct subsets of effector CD4+ T cells87-89 depending on the cytokine milieu at the time
of activation (Figure 2). The CD4+ T cell subsets are defined by the cytokines they produce
and the expression of specific transcriptional factors.90-98

10

2.5.4.1 Role of TH1 cells in viral infections
CD4+ effectors generated in response to viral infection are mainly TH1,
characterized by strong IFN-γ production, due to exposure to high levels of interleukin-12
(IL-12), interferon gamma (IFN-γ) and type I interferons in the priming milieu.85, 99-101 TH1
cells produce antiviral cytokines, such as IFN-γ, tumor necrosis factor alpha (TNFα), and
interleukin IL-2 (IL-2) which are involved in generation of cytotoxic T cells, and activation
of innate immune cells such as natural killer (NK) cells and macrophages.85, 102-104
IL-2 produced by TH1 cells attracts NK cells to sites of infection and stimulates
them to produce IFN-γ.105 A study conducted by Janssen et al.,106 using C57BL/6 mice
immunized with adenovirus 5 E1- transformed Tap-/- mouse embryo cells showed that
depletion of CD4+ helper T cells before immunization, blocked the production of antigenspecific cytotoxic T lymphocytes (CTLs) after secondary in vitro re-stimulation. Addition
of IL-2 to primary effectors rescued this secondary expansion defect.106 Thus IL-2 is critical
in the development of memory CTLs possibly by sustaining CD8+ T cell proliferation or
by enhancing survival of antigen-specific CTLs.107 Similarly, studies with IL-15 and IL-15
receptor deficient mice show a potent primary CD8+ T cell response to infection with
lymphocytic choriomeningitis virus (LCMV) that was phenotypically and functionally
similar to CD8+ T cell response present in IL-15+/+ mice. But longitudinal analysis revealed
a decrease in virus-specific memory CTLs in IL-15−/− mice due to a severe defect in the

11

proliferative renewal of antigen-specific memory CD8+ T cells.108 Thus, cytotoxic T
lymphocytes generated with CD4+ T cell help are long-lived, functional memory cells that
can respond quickly to re-challenge with virus. These studies underpin the role of CD4+
helper T cells in programming the development of CD8+ T memory cells and the
application of this knowledge to the development of vaccines and thereauptics that enhance
memory T cell responses.
IFN-γ has been shown to upregulate both major histocompatibility complex class I
(MHC I) and major histocompatibility complex class II (MHC II) expression, activate
macrophages in an antigen-specific fashion, and induce several IFN-inducible antiviral
mechanisms.102, 103 During hepatitis C virus (HCV) infection, ability of T cells to produce
IFN-γ is significantly associated with decreased viremia and reduced risk of chronic
infection.109 Hepatitis B virus (HBV) studies show that IFN-γ inhibits hepatitis B virus
(HBV) DNA replication in hepatocytes.110-112 The critical role of IFN-γ in viral infections
was demonstrated in mice lacking IFN-γ and IFN-γ receptor. The mice were highly
vulnerable to lethal west Nile virus (WNV) infection with mortality rates rising for 30%
(wild type mice) to 90% (IFN-γ-/- or IFN-γR-/- mice).113
The role of TNF-α in viral infections is demonstrated in patients with autoimmune
disorders who develop subfulminant hepatitis B infection after infusion with infliximab (a
chimeric monoclonal antibody against TNF-α) due to an unrecognized HBs-antigen carrier
state.114-116
2.5.4.2 Role of TH2 cells in viral infections
TH 2 cell responses were thought to drive optimal humoral immune responses
through production of IL-4. However, adoptive transfer of TH1 cells, and TH 2 cells,
12

demonstrated that IFN-γ (produced by TH1 cells in response to viral infections) mediates
IgG2a class-switch responses.117, 118 In 1987, Jean-Paul et al., infected mice with a panel of
11 RNA and DNA mice viruses. Their data identifies IgG2a as the predominant antiviral
isotype in these mice.119 In fact, TH2 cell responses are not protective but drive immune
mediated injury during infection with several viruses including, influenza virus,120,

121

respiratory syncytial virus (RSV),122 herpes simplex virus (HSV)123 and vaccinia virus.124
2.5.4.3 Role of TH17 cells in viral infections
The role of TH17 effector responses to viral infections is not well understood, but
IL-17-producing CD4+ T cells responses are generally considered to be detrimental to the
host due to immune mediated injury caused by recruitment of neutrophils to the infected
site.125-129 However, in several viral infections, TH17 cells could be necessary to prevent
disease exacerbation.130, 131
Infection with Theiler’s murine encephalomyelitis virus infection induces
development of TH17 cells in vitro and in vivo in an IL-6–dependent manner.132 The IL-17
cytokine produced by these cells was shown to promote viral persistence by upregulating
antiapoptotic molecules and consequently enhancing the survival of virus-infected cells.
Also, neutralization of IL-17 augmented virus clearance and enhanced the cytotoxic
function of T cells.132 Contrary to these findings, McKinstry et al.,133 show that TH17polarized CD4+ T effectors can protect against high doses of flu (in the absence of IL-10)
and that this response is IFNγ-, perforin- and IL-17A-independent. This protection could
be mediated by recruitment of neutrophils to the site of infection130 since IL-I7 has been
shown to promote granulopoiesis (via granulocyte colony-stimulating factor (G-CSF)) and
upregulation of CXC-chemokines that promote neutrophil recruitment.134
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Unique CD8+ T cytotoxic (Tc) 17 cells which are CD8+RORγt+ IL-17-secreting T(Tc17)
cells have been shown to protect mice from lethal influenza virus challenge.131 The Tc17
cells are unique in that they produce IL-17A and IL-17F, and lack perforin and granzyme
B expression and have no cytolytic activity. Tc17 protection is accomplished by great
neutrophil influx into the lung of infected mice and production of IFN-γ.131
TH17 cells often produce significant levels of IL-21 and IL-22 in addition to IL-17.133 The
role of IL-22 is not extensively studied in viral infections but IL-22 has been shown to
promote tissue repair via upregulation of defensins.135 IL-21 is involved in sustaining CD8+
T cell responses during chronic viral infection.
TH17 cells are necessary for host defense against some extracellular bacteria and
fungi. Therefore, viral infections like HIV that deplete Th17 cells allow opportunistic
infections in the gut to take hold.136, 137 In this regard, Th17 are very critical in preventing
disease exacerbation that could result into host death.
2.5.4.4 The role of CD4+ T regulatory cells (Tregs) in viral infections
Studies aimed at understanding the role of antigen - specific T regs have been
reported in models of chronic infection. The outcome of Treg responses can be beneficial
or detrimental depending on the infecting virus. In a herpes simplex virus model, mice
depleted of CD25+ T‐cell (nTregs) had enhanced in vivo CD8+ T‐cell proliferation and
cytotoxicity responses to the immunodominant peptide. This response was three-fold the
response observed in animals with intact nTregs.138 In HCV studies, patients with persistent
HCV infection were shown to have a higher frequency of CD4+CD25+ T cells than
recovered persons, and these nTregs could directly suppress the HCV‐specific reactivity of
CD8+ T cells ex vivo.139 Targeting and disrupting of Tregs by viruses like HIV may
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contribute to hyperactivation of conventional T cells which could hasten progression to
AIDS.140, 141In most viral infections it seems like nTregs work to dampen the efficacy of
protective immunity hence contribute to persistence and perhaps chronic disease.142 It is
also evident that Tregs profoundly inhibit T cell activation, proliferation and effector
function which can limit the immunopathology caused by persistent high level of immune
stimulation from chronic viral infections.142, 143
2.5.4.5 The mechanism of CD4+ T help to CD8+ T cells
During viral infections, CD4+ T helper cells (CD4+TH) promote engagement of
CD8+ T cells with antigen presenting cells (such as dendritic cells; figure 3). Dendritic cells
(DCs) upon cognate interaction with CD4+TH increase their ability to attract/retain (get
‘licensed’) antigen specific CD8+ T cells.144-147 However, some authors think that this
pathway may be of minor importance since APCs can be activated effectively by viruses
through PRRs without help from helper cells.148-151 Nevertheless, the absence of CD4+ T
help has been shown to compromise the generation of primary cytotoxic T lymphocyte
(CTL) responses to vaccinia virus (VV),152 herpes simplex virus (HSV)147 and influenza
virus.153, 154
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Figure 3: Dendritic cell licensing and killing of target cells by CTL
The generally accepted model of APC licensing suggests that CD4+TH
activate/‘lincense’ DCs to attract naïve CD8+ T cells (figure 3). Viruses use two routes to
enter host cells: 1) Receptor mediated entry which involves the virus binding to its receptor
on DCs. In this route, the virus replicates and viral proteins generated during replication
are degraded into peptide fragments and presented by MHC class I molecules to CD8+ T
cells155; 2) Through pinocytosis, DCs capture viral particles or remnants of virus infected
cells. These antigens are processed, and cross presented by MHC class II to CD4 + TH.
CD4+TH then upregulate CD40L expression and, through interaction with CD40, activate
DCs to upregulate the expressing of CD80/CD86 marker.146,
16

156-158

Interaction of

CD80/CD86 with CD28 activates CD8+ T cells to differentiate into cytotoxic cells that
induce apoptosis of virus infected cells by release of cytotoxic granules, and the production
of TNF-α and IFN-γ.85, 155 Thus CD4+ TH provide help to CD8+ T cells indirectly by
activating APCs through CD40.148
2.5.4.6 CD4+ T follicular helper (TFH)cells help for B cells
The expression of SLAM-associated protein (SAP) by TFH promotes the formation
of germinal center and drives production of memory B cells and long-lived plasma cells.159,
160

TFH cells provide help to cognate B cells via the expression of CD40L,161 inducible T

cell co-stimulator (ICOS),162 IL-21,163 IL-4161, 164 and other molecules.165
2.5.4.7 Antiviral functions of CD4+ T lymphocytes
CD4+ T cells have potent protective roles that are independent of their helper
functions. First, CD4+ T cells produce cytokines (such as IFN-γ and TNFα) that induce an
antiviral state at infected sites. Second, CD4+ T cells have a direct cytotoxicity function.
2.5.4.7.1 Induction of an antiviral state
IFN-γ and other interferons induce proteins that contribute to the antiviral state.
One of these proteins is the double stranded RNA dependent enzyme 2’5’- oligoadenylate
synthetase which activates the oligomerization of ATP. The 2’5’ ATP oligomers activate
an RNAse that can cleave both cellular and viral RNAs.166, 167 The second protein is the
double stranded RNA dependent protein kinase known as protein kinase R which inhibits
virus and host cell protein synthesis by directly phosphorylating the α subunit of the
translation initiation factor elF-2.168, 169 The third is a group of proteins referred to as Mx
proteins, are highly conserved large GTPase that inhibit the trafficking or activity of virus
polymerases.170, 171
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2.5.4.7.2 Direct cytotoxicity of CD4+ T lymphocytes
Cytotoxic CD4+ T cells have been reported in γ-herpesvirus 68,172 dengue virus,173
lymphocytic choriomeningitis virus174 and friend retrovirus.175 These cells express the
degranulation marker, CD107,172 and the cytotoxicity is perforin and FASL mediated.176,
177

The transcription factor eomesodermin (Eomes) is crucial in driving the development

of cytolytic CD4+ T cells in vivo. Dual costimulation (DCo) through OX40 and 4-1BB is
responsible for activating Eomes to program naïve CD4+ T cells into cytotoxic TH1 cells.178
Low antigen dose and early IL-2 signals have also been shown to play a role in the
differentiation of CD4+ T cells into cytotoxic cells.179
2.5.4.8 The role of CD4+ T lymphocytes in equine viral infections
Bovine papillomavirus (BPV) infections of the equine species causes sarcoid.
Equine sarcoids have been shown to contain a large number of CD4+ CD8+ dual positive T
cells which express FOXP3 a key transcription factor of regulatory T cells. Regulatory
cells allow the persistence of lesions by dampening protective antiviral response.180
2.5.4.9 Summary
On activation, naïve CD4+ T cells differentiate into distinct subsets i.e. TH1, TH2,
TH17 and TFH, and we have discussed how each of these subsets contribute to viral
infections. The common denominator of these effector subsets is to produce cytokines that
not only establish an antiviral state but also program the development of memory CD8+ T
cytotoxic cells. Another key role is the provision of help to B cells for development of
germinal centers and long-lived memory humoral response. CD4+ T cells carryout a
variety of functions that could differ depending on the site of infection, the infecting
pathogen and the level of infection. Sometimes the different mechanisms utilized by the
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effector subsets synergize to produce a robust T cell response.
2.5.5 Role of CD8+ T lymphocytes cells in viral infections
The role of Cytotoxic T lymphocytes (CTLs) in viral infections was first
demonstrated by Zinkernagel and Doherty in LCMV infected mice. In this study, spleen
and lymph node cells from infected mice lysed mice fibroblasts infected with LCMV in a
chromium release assay.181, 182 A few years later, transfer of CTL clones into influenza A
infected mice showed antiviral effects which were mediated by killing of virus-infected
cells.183, 184 Similar results were obtained with studies in respiratory syncytial virus185, 186 and
herpes simplex virus.186
CD8+ T cells typically mediate protection against intracellular pathogens and
tumor cells. They are the major contributors to antiviral T cell immunity. The role of CD8+
T cells in viral infections has been investigated in various viral infections including HIV,
HBV, HCV, LCMV, influenza virus and others. CD8+ T cells recognize cognate antigen
presented via major histocompatibility complex class 1 (MHC1). In the presence of costimulatory signals, antigen-specific CD8+ T lymphocytes undergo clonal expansion and
differentiate into cytotoxic T lymphocytes (CTL) that produce cytolytic granules and other
factors (such as IFN-γ and TNF-α).
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2.5.5.1 CTL response in hepatitis B Virus (HBV) infections
HBV is a hepatotropic DNA virus in the hepadnaviridae family. It causes both acute
and chronic liver infections. Despite significant vaccination and antiviral therapy
programs, HBV-related sickness still accounts for about one million deaths annually.
Strong HBV specific CD8+ T cells responses have been correlated with viral
clearance during acute infection.187 CD8+- depletion studies confirm that these cells are the
main effector cells responsible for viral clearance and disease pathogenesis during acute
HBV infection.188 Depletion of CD8+ T cells prolonged the infection and delayed the onset
of viral clearance until CD8+ T cells reappeared and entered the liver.188 The mechanisms
through which CD8+ T cells mediate viral clearance during HBV infection are both
cytolytic and non-cytolytic. The contribution of non-cytolytic effector mechanisms is
supported by findings in a cell culture model, where virus-specific CD8+ T cells were able
to inhibit HBV replication with minimal cell lysis. IFN-γ and TNF-α are the mediators of
these effector mechanisms since blocking these cytokines abrogated non-cytolytic
functions.189
The HBV core protein (HBcAg) has an intrinsic ability to activate the immune
system since many epitopes generated from the core protein can efficiently crosslink B cell
receptors.190 Assessment of liver tissue from acutely infected patients revealed an
overwhelming B cell response targeting HBcAg.191 It is hypothesized that small amounts
of soluble HBcAg are released into the blood stream following viral particle destruction or
cytolysis of infected hepatocytes. These antigens are captured by B cells and presented to
CD4+ T lymphocytes.192 This is supported by Li et al.,193 who demonstrated the presence
of HBcAg-specific IL-21-producing CD4+ T cells (in acute patients) that enhanced the
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production of IFN-γ and perforin expression by CD8+ T cells from chronic HBV patients.
Thus CD4+ T cells might contribute to HBV control by sustaining CD8+ T cells. These
findings show that, HBcAg can induce an immune response involving CD8+ T cells, and B
cells that produce antiviral antibodies. Based on this knowledge, a novel HBV vaccine was
designed, and shown to induce both T and B cell responses in mice. The vaccine
formulation comprised of particulate hepatitis B surface (HBsAg) and core antigen
(HBcAg). It induced multifunctional HBsAg- and HBcAg-specific CD8+ T cells detected
by staining for IFN-γ, TNF-α and IL-2, as well as high antibody titers against both
antigens.194
In chronically infected individuals, virus-specific CD8+ T cells are rarely detectable
in peripheral blood due to functional T cell exhaustion caused by persistent antigen
stimulation. Consequently, CD8+ T cells have elevated levels of exhaustion markers such
as programmed death-1 (PD-1), cytotoxic T lymphocyte antigen 4 (CTLA4), Tim-3 and
2B4.195 Furthermore, elevated levels of PD-1 ligand have also been reported in hepatocytes
during HBV infection.196 Expression of these exhaustion markers will lead to apoptosis and
subsequent deletion of the CD8+ T cells. CD4+ T cells also display functional exhaustion
in chronic HBV. The loss of CD4+ T helper cells may prevent the maturation of functionally
efficient CD8+ T response.
2.5.5.2 CTL response in human immunodeficiency virus (HIV) infection
The HIV epidemic is one of the main global health challenges. Design of vaccines
and drugs have been complicated by the virus’s rapid evolution to evade the immune
system, drug toxicity and drug resistance.
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Cytotoxic T lymphocytes were first shown to suppress HIV by two studies in 1994,
which showed a strong CTL response (during the acute stage) that correlated with low
viremia and this response preceded the production of neutralizing antibodies.197, 198 CD8+
T cells produce a soluble factor that was shown to suppress human immunodeficiency virus
(HIV) long terminal repeat (LTR)-mediated gene expression in human CD4+ T cells. This
factor is known as CD8+ T antiviral factor (CAF).199-203 The CAF and β-chemokines
mediate the CD8+ T cell non-cytotoxic antiviral response (CNAR).199, 203 Beta-chemokines
suppress HIV replication by binding to their cognate chemokine receptors, thereby
blocking HIV from using these receptors for binding and entry into cells.199, 204 CNAR
occurs early in HIV before antibodies are produced202, 205 and thus could be responsible for
the initial reduction in viremia observed during acute infection.206, 207 Individuals who
repeatedly get exposed to HIV but remain uninfected, or individuals who do not progress
to AIDS without antiretroviral therapy, have been shown to have a strong CNAR.208, 209
Both the cytotoxic and non-cytotoxic pathways have been reported to correlate with
delayed disease progression in HIV-infected individuals.210-212
A single individual can express up to six different HLA class I alleles: two from
each of the following MHC class I loci HLA-A, HLA-B and HLA-C. HIV positive
individuals who are homozygous for one or more HLA loci progress rapidly to AIDS and
death, while maximum heterozygosity delayed onset of disease (10 or more years).213, 214
This implies that the diversity of HIV- specific CTL epitopes is very important in
determining disease outcome. However, recognition of a single epitope has been associated
with effective control of viremia.215 Thus certain CTL specificities could be more
efficacious than others. Indeed, CTL responses directed at conserved viral proteins are
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associated with lower viremia than responses directed at variable proteins.216, 217 This is
why certain HLA alleles are associated with long-term non-progression while others are
associated with rapid progression to AIDS.218-220
CTL escape in HIV was first described by Koenig et al.,221 who transferred a CTL
clone that was specific for the conserved region of negative factor (nef) protein into an HIV
patient. Instead of supplementing the CTL response, the infusion caused decline in
circulating CD4+ T cells and a rise in viral load. Furthermore, HIV isolates from plasma or
CD4+ T cells lacked the nef epitope, implying that CTL selected for mutants of the protein
being recognized. CTL escape has been shown to occur in acute stage197, 222, 223 as well as
chronic stage of HIV.215 CTL escape was described in two HIV patients who rapidly
progressed to AIDS after it occurred.215 Besides CTL selection, HIV evades immune
recognition by downmodulating surface expression of HLA-A and HLA-B224, 225 but not
HLA-C or HLA-E.226 This does not only reduce killing by HLA-A and HLA-B restricted
CTLs, but it also blocks natural killer cells from killing virus infected cells.227
T cell exhaustion is very common in chronic infections inclusive of HIV. Infection
with HIV results into chronic immune activation which leads to progressive loss of CD4+
T and CD8+ T cells. Exhausted T cells show progressive loss of function characterized by
loss of IL-2 production, proliferation and effector functions.228 Expression of T cell
exhaustion markers such as PD-1 and Tim-3 have been associated with HIV disease
progression in cross sectional studies.229 The main route through which HIV affects the
immune system is by infection of CD4+ T cells. Diminished numbers and function of CD4+
T cells impairs CD8+ T cell function because CD4+ T cells are required in the maintenance
of memory CD8+ T cells and proliferative renewal.230
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2.5.5.3 CTL response to influenza virus
Influenza is an acute respiratory disease caused by RNA viruses belonging to the
orthomyxovirus group. The ability of these viruses to constantly and rapidly change genes
encoding for their surface proteins has made it quite challenging to develop effective
vaccines. The majority of CTLs are directed at conserved epitopes such as epitopes located
in the internal portion of the nucleoprotein (NP).231, 232 Thus, these CTLs are broadly crossreactive and recognize all major subtypes. However, CTL response directed at these
conserved parts of NP is transient and partially protective.233
Although influenza infection in mice does not simulate the natural infection in
higher vertebrates, mouse models have been critical in understanding the T cell response
to influenza virus. To investigate the role of CTL response in influenza infection, Bender
et al.,234 used transgenic mice homozygous or heterozygous for beta 2-microglobulin gene
(β2M). The homozygous mice lack MHC class 1 CD8+ T cell restriction. Challenge with a
virulent strain of influenza virus caused a significantly high mortality in homozygous mice
compared to heterozygous mice. Furthermore, a non-lethal challenge caused significant
delay in pulmonary viral clearance in β2M (-/-) mice.234 In another mouse model, using Bcell deficient mice shows that these mice have a 50-100 fold greater susceptibility to lethal
influenza A infection than wild type. Adoptive transfer of influenza A specific CD8+ T cell
clones promoted recovery from lethal infection.235 These studies highlight the protective
role of CTL, however, vaccination with influenza dominant proteins confers mild CTLmediated protection.236-239 Thus an efficacious immune response against influenza could
be mediated by antibodies. Indeed, using transgenic mice expressing a uniform TCR
heterodimer (αβ4/β11; termed F5-Tg) derived from an NP specific T cell clone obtained
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from C57BL/10 mice, Moskophidis et al.,233 were able to track effector CTL functions in
situ. Their data indicate that CD8+ T cells only conferred protection at low viral dose
challenge, at high viral dose they exacerbated viral pathology and increased mortality.
2.5.5.4 Role of CTL response in equine viral infections
2.5.5.4.1 Equine infectious anemia virus (EIAV)
EIAV is a lentivirus that causes disease in horses worldwide. More than 90% of
infected horses progress to the inapparent carrier state during which time they have
persistent low viral loads. CTL response is associated with control of primary viremia in
EIAV infected horses. This was demonstrated in Arabian SCID foals.240 SCID horses lack
functional T and B lymphocytes and thus are incapable of launching a functional adaptive
response. Indeed, SCID horses failed to eliminate virus from their plasma during primary
infection while normal horses eliminated the virus.240 Furthermore, immune reconstitution
of an SCID foal with virus-specific cytotoxic lymphocytes prevented continuous EIAV
infection.241 Recurrence of viremia in EIAV infected horses is caused by antigenic
variation. Antigenic drift of EIAV has been demonstrated with autologous neutralizing
antibodies242, 243 and CTL epitopes.244 During EIAV infection, neutralizing antibodies are
observed after clearance of primary viremia245, 246 and the CTL response has been correlated
with this initial clearance of viremia.247 So, CTL response is a very critical part of the
immune response to EIAV.
Antigen-specific CTLs that do not require in vitro stimulation have been detected
(in 21Cr release assay) but disappear 3 months after infection.248 CTL memory to EIAV has
been observed at least 7 years after infection.248 CTL epitopes have been mapped using
retroviral vector-transduced target cells expressing different Gag proteins and overlapping
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synthetic peptides.249, 250 Other epitopes have been mapped in the Env251 and Rev
proteins.251
2.5.5.4.2 Equine herpesvirus 1 (EHV 1)
Equine herpes virus 1 is a highly prevalent respiratory virus of horses worldwide.252
Infection of horses is characterized by fever, respiratory distress, abortion and severe
neurological sequelae.253 EHV-1-specific, CTL response has been detected in equine
PBMCs of EHV-1 infected and vaccinated horses.254, 255
A murine model of EHV-1 that closely mimics infection in the natural host showed
the generation of primary and memory virus specific CTL response to the attenuated EHV1 strain KyA. In this model, primary virus-specific CTL response was detected in draining
mediastinal lymph nodes 5 days following infection.256 Also, EHV-1 CTL response was
detected in the spleen up to 26 weeks after the resolution of the infection. Adoptive transfer
of splenocytes (containing high levels of CD4+ and CD8+ cells) from KyA immune mice
into irradiated mice infected with EHV-1 RacL11 strain caused a greater than 250-fold
reduction of RacL11 in the lung. Depletion of both CD4+ and CD8+ cells from splenocytes
abrogated the clearance of RacL11.256 Similarly, transfer of spleen cells from Balb/C mice
primed with EHV-1 AB4 conferred protection in recipient mice.257 To confirm that this
response was mediated by T cells, recipient mice were tested for delayed hypersensitivity
(DTH). Recipients of spleen cells from primed mice had a higher DTH response than
controls.257
Pregnant mares that exhibit high frequencies of circulating EHV-1 specific CTL
response have an enhanced protection against EHV-1 induced abortion and other clinical

26

signs.258 Similarly, ponies with high frequencies of precursor CTLs were protected against
EHV-1 challenge showed by reduced or absence of clinical signs.259
2.5.5.4.3 Equine arteritis virus (EAV)
Although humoral immunity to EAV has been studied extensively, little is known
about the role of T cell response to EAV in both non-carrier and carrier horses. There is
only one study showing EAV specific CTL precursors being detected at 4 months post
infection and persisting for at least 1-year post infection.260 Significant infiltration of T
lymphocytes, macrophages and dendritic cells into the reproductive tract of carrier horses
has been reported.76 But, the role of these cells is not known since EAV still persists in the
presence T lymphocytes.
2.5.6 Cytotoxic T Lymphocyte killing mechanisms
Cytotoxic T Lymphocytes use three pathways to kill infected target cells: the FasFasL pathway, granzyme-perforin pathway, and secretion of cytokines such as IFN-γ and
TNF-α.261, 262 TNF-α binds to its receptor on target cells and triggers the caspase cascade,
leading to apoptosis.263 IFN-γ upregulates the expression of MHC class I antigens and Fas
molecules in target cells, leading to enhanced presentation of foreign antigens and
increased Fas-mediated target-cell lysis.261
Fas (also known as CD95 or APO-1) is a type I transmembrane protein, containing
a death domain (DD) in its cytoplasmic region.264, 265 The interaction of Fas with its ligand
(FasL) triggers apoptosis through recruitment of the adaptor protein Fas-associated death
domain (FADD) and binding of procaspase-8.266 The interaction of FADD, procaspase 8
and DD results in the formation of the death-inducing signaling complex (DISC)267 which
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finally leads to the activation of effector caspase-3 by active caspase-8 (figure 4). The
tumor necrosis factor receptor (TNFR1) also contains a death domain, that utilizes FADD
and TRADD (TNFR1-associated death domain protein) to induce apoptosis via activation
of caspase-8.263

Figure 4: Fas-FasL and Granzyme pathways
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After a CTL recognizes its target, cytolytic granules move to the synapse by
exocytosis.268, 269 The granules are then deposited into the synaptic cleft where they become
endocytosed by the target cell.270 Cytotoxic granules contain a pore-forming protein
perforin and a group of serine proteases called granzymes.268 Perforin polymerizes into
transmembrane channels that inflict osmotic stress and facilitate target cell uptake of
proapoptotic granzymes.271, 272 Granzymes can also enter the target cell independent of
perforin by endocytosis (figure 4) after initial electrostatic binding to the membrane of the
target cell.273-275 Mice and humans lacking perforin are severely immunocompromised as
evidence by the lack of LCMV clearance in perforin deficient mice276 and the presence of
a potentially fatal immunoregulatory disorder, type 2 familial haemophagocytic
lymphohistiocytosis (FHL) in humans with congenital perforin deficiency.277, 278
Multiple granzymes (Granzyme A-M) have been reported. The mouse has nine, the
rat has eight rat and the human has five granzymes.270 Granzyme A and B are the most
abundant. Granzyme A induces single-stranded DNA damage as well as rapid loss of cell
membrane integrity and destroys the nuclear envelope by targeting lamins and unwinds
DNA for degradation by targeting histones.279-281 Granzyme B mediated apoptosis is both
caspase dependent and caspase independent. In cells treated with perforin loaded
granzyme, caspases 3 is directly processed by granzyme B.282, 283 Granzyme B can also
cleave BID (BH3-interacting domain death agonist) to activate the mitochondrial apoptotic
pathway.284, 285 It induces DNA damage by degrading the inhibitor of caspase-activated
DNAase (ICAD).286 Caspase-activated DNAase (CAD) exists as a heterodimer with ICAD
(figure 4). In this form CAD is inactive.287-289
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Granzyme B is the most potent activator of caspase-mediated, as well as caspaseindependent, cell death. In vitro CTL assays exploit this pathway to study CTL killing by
measuring the presence of granzyme B activity in target cells.290 To increase the precision
of these assays, upstream caspases are also incorporated into the assays by using
fluorescently labelled inhibitors of caspases to detect active caspases in target cells.291
2.5.6.1 Stages of CTL killing
2.5.6.1.1 Target cell recognition and formation of the immunological synapse
Migrating CTLs recognize target cells by engaging the TCR to recognize peptideMHC complexes on target cells, which initiates signaling to form the immunological
synapse (IS). The IS forms at the point of contact between the CTL and the target cell. It
forms

a characteristic bullseye pattern made up supramolecular activation clusters

(SMAC). 292-294 The center (cSMAC)of the IS is made up of T cell receptor clusters, the
periphery(pSMAC) is made up of intergrins and the distal (dSMAC) is made up of
phosphatases and actin.295, 296
2.5.6.1.2 Polarization of the CTL and degranulation
The formation of the IS induces polarization of the CTL by initiating the movement
of the centrosome (microtubule organization center).296, 297 The centrosome moves from
the uropod to the point of TCR signaling i.e. edge of the cSMAC forming the secretory
domain. Cytotoxic granules move along the microtubules towards the polarized
centrosome and are secreted at the secretory domain of the IS.297 The granules are formed
in membrane bound vesicles when CD8 cells differentiate into CTLs. The
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vesicles at the secretory domain fuse with the CTL membrane and are released into the
synaptic cleft towards the target cell.298
2.5.6.2 Stages of cell death
2.5.6.2.1 Apoptosis
After delivery of cytotoxic granules by CTLs, the target cell begins to undergo
apoptosis, a form of programmed cells death.299-302 There are three apoptotic pathways: the
extrinsic or death receptor pathway, the intrinsic or mitochondrial pathway and the
granzyme/perforin pathway.
The extrinsic pathway is initiated by death receptors which are members of the tumor
necrosis factor (TNF) receptor gene family.301, 303 The best described models of this pathway
are the Fas and TNF-α described above. The perforin/granzyme pathway is a variant of type
IV hypersensitivity since sensitized CD8+ cells kill antigen baring cells. The intrinsic
pathway is initiated by a diverse array of non-receptor-mediated stimuli that leads to opening
of the mitochondria permeability transition (MPT) pore, loss of mitochondrial
transmembrane potential and release of cytochrome c which binds to Apaf-1 as well as
procaspase -9.304 Another molecule, apoptosis-inducing factor (AIF) translocates to the
nucleus where it causes DNA fragmentation.305
The extrinsic and intrinsic pathways end at the execution phase, where the
activation of executioner caspases takes place. Caspases -3, 6 and 7 function as effector or
executioner caspases. Caspase -3 is the most important executioner and is activated by any
of the initiator caspases i.e. caspase -8, 9 or 10.306 Activation of executioner caspases
activates cytoplasmic endonucleases that degrade nuclear material, and activates proteases
that degrade the nuclear and cytoskeleton proteins.300
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As the cell undergoes apoptosis, the chromatin condenses, the membrane blebs and
its DNA fragments.302 Phosphatidylserine (PS) is normally confined to the cytoplasmic
face of the plasma membrane. During apoptosis it translocates to the cell surface.
Externalization of PS signals to neighboring cells such as macrophages to remove the dying
cells by phagocytosis.307 Once PS is externalized, it can be detected by fluoresceinisothiocynate - labeled annexin V using flow cytometry or fluorescence microscopy.307
2.5.6.2.2 Secondary necrosis
This is a phenomenon referring to progressive loss of plasma membrane integrity
of apoptotic cells. It happens when apoptotic cells are not efficiently removed by
scavenging cells or when cells are infected by apoptotic inducing pathogens such as
vesicular stomatitis virus or encephalomyocarditis virus. Caspase-3 has been shown to
trigger necrosis of apoptotic cells.308
Loss of membrane integrity associated with apoptosis leads to unidirectional
leakage of molecules. The presence of these molecules (e.g. lactate dehydrogenase) in the
culture medium of cell under CTL attack has been used to measure CTL response.
2.6 Assays to measure T cell cytotoxicity
For many years the chromium release and limiting-dilution assays were the only
techniques used to measure antigen specific T-cell responses. During the past ten years or
so, new methods to analyze T-lymphocyte responses have been developed. These new
methods are more sensitive, less hazardous and provide more information on the
functionality of T cells. T cell assays used to monitor T cell immunity to infection or
vaccination can be divided into three groups: Functional assays, assays based on structural
features of the T cell receptor (TCR) and assays that detect precursor T cells.309
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2.6.1 Functional assays
These are mainly the interferon gamma (IFN-γ) enzyme-linked immunoSpot (IFNγ ELISpot) assay and intracellular cytokine staining assay (ICS). The ELISpot assay
measures antigen-specific lymphocyte frequency by measuring the secretion of cytokines
or other immune proteins that are engaged in the cytolytic pathway.310-312 ELISpot assays
are conducted in antibody coated plates and the secreted proteins are detected locally (as
spots) by the capture antibody.310 The ELISpot assay offers quantitative data, uses low
numbers of effector cells, is easier to perform, and highly specific and sensitive. The IFNγ ELISpot assay however, on its own is not sufficient to detect cytotoxic cells as T cells
with cytotoxic activity do not always secrete IFN-γ.313-315 A modification of the IFN-γ
ELISpot, the Granzyme B(GrB) ELISpot assay may be better at detecting cell-mediated
cytotoxicity, since GrB is a key mediator of target cell death in vivo.316-318 However, GrB
ELISpot assay may not work in cases where the target cells contain serpin proteinase
inhibitor 9 (a GrB inhibitor) or if effector cells are perforin deficient.314, 315
For intracellular cytokine staining, cells are treated with golgi inhibitors such as
monensin or brefeldin A, so the cytokines accumulate in the cytoplasm of these cells upon
antigen activation. After fixation and permeabilization of the lymphocytes, intracellular
cytokines can be quantified by flow cytometry.319-322 Thus, ICS does not only allow the
measurement of cytokine secreting cells but also gives the phenotype of cells that produced
these cytokines.322 The quantity of cytokine produced per cell is also enumerated.
Combining this assay with tetramer staining allows the detection of rare cell populations.323
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2.6.2 Assays that assess the structural features of the TCR
Fluorescently labelled MHC-peptide complexes that bind the T Cell Receptor
(TCR) can be used to visualize antigen-specific T cells.324-327 Since the interaction between
TCR and MHC-peptide complexes is too weak for stable binding, multimers of MHCpeptide complexes are used to increase the overall avidity for the T cell.309 To construct
these multimers, the heavy and light chains of the MHC are cloned and produced in
Escherichia coli, solubilized and refolded in the presence of high concentrations of the
antigenic peptide. The C-terminals of these refolded complexes are then labelled with a
single biotin and the complexes are incubated with fluorescent streptavidin.328 Dimers,
tetramers or even pentamers of both MHC I and MHC II have been produced and used in
flow cytometry to characterize T cell responses.329-331 This assay does not provide clues on
the functionality of the T cells since it only allows visualization of peptide specific T cells.
Thus, it’s important to couple this assay to phenotypic characterization of the T cells to
determine if the responding T cells are effectors, functional or anergic.332 Also, T cell
clones can be isolated using tetramers and enriched without the need for several cycles of
in vitro stimulation.333 Tetramer analysis is very sensitive,283, 298, 308 quick to perform, and
uses a small number of cells. However, its reliability varies with cell type as lack of staining
for T cell clones has been reported and not all peptides form functional tetramers. Also,
tetramer positive T cells are not always cytotoxic and tetramers can only be used to detect
T cell responses to known antigens.334
Antigen-specific T cells can also be phenotypically detected by PCR, by
sequencing the third complementarity-determining region 3 (CDR3) of the TCR.335, 336
This is achieved by using clone-specific primers that flank the CDR3. The CDR3 region
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encodes the highly polymorphic portion of the TCR responsible for recognizing peptideMHC complexes. For the β chain, the CDR3 region encodes the V-D segment and D-J
segment junctions, whereas for the α-chain, it encodes the V-J junction. Using V, D, or J
region subfamily-specific PCR primers, the development of restricted TCR gene usage can
be analyzed.337 T cells of the same clone will have the same profile.338 This assay is very
sensitive, robust and less susceptible to handling or culture methods. TCR CDR3 can also
be used in combination with tetramer analysis to confirm the phenotype of tetramer
positive cells.
2.6.3 Assays that detect precursors of T cells
2.6.3.1 Proliferation assay
In this assay, purified T cells or PBMCs are mixed with various dilutions of antigen
or in the presence of antigen presenting cells. Then the ability of T cells to proliferate is
measured after 72-120 hrs of stimulation using [3H]thymidine by quantifying the amount
of

radiolabeled

thymidine

incorporated

into

the

DNA

or

the

amount

of

bromodeoxyuridine(BrdU) incorporated by dividing cells.339-341 Its major advantage is that
it can be performed directly on peripheral blood samples without in vitro stimulation thus
giving data that correlates well with T-cell response in vivo. Its major disadvantage is that
it can be influenced by the nonspecific immune response of test subjects. Also, the
calculated stimulation index does not necessarily correlate with the number of antigenspecific T cells present in vivo. For instance, high levels of proliferation by a few cells or
low levels of proliferation by many cells would give a similar stimulation index.334
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2.6.3.2 Direct cytotoxicity assays: the chromium release assay (CRA)
The CRA is based on the ability of CTL to lyse 51Cr-labeled target cells loaded with
the antigen of interest. After incubation of target cells with the antigen of interest, the target
cells are labeled with 51Cr. Labeled target cells are then incubated (at different effector to
target ratios) with effector cells that have been expanded in vitro for 7-21 days.342 Target
cells that are recognized and lysed by the effector cells subsequently release 51Cr into the
supernatant, the chromium is then quantitated by scintillation γ counting.8 The CRA has
been considered ‘the gold standard’ to measure CTL activity, but its many drawbacks have
forced researchers to develop less hazardous and more sensitive techniques. Besides the
CRA using hazardous material, it’s not very sensitive, sometimes effectors have to be
stimulated many times to get a response. This response might not mirror in vivo response
because the phenotype of effectors can change during these repeated cycles of stimulation.
Other disadvantages include: poor labelling of some target cells, high background due to
spontaneous release of 51Cr from certain target cells and it is semiquantitative.
Several nonradioactive CTL assays have been developed as alternatives to the
CRA. These assays are based on release of nonradioactive probes, detection of enzymatic
activity, analysis of targets cells transfected with foreign enzyme genes, detection of early
activation of effectors, or measurement of apoptosis or necrosis in target cells.309 Among
the assays that measure apoptosis or necrosis in target cells, is the colorimetric
measurement of lactate dehydrogenase (LDH) activity in the culture medium. The LDH
assay uses the same procedure as the CRA but the target cells are not labelled with 51 Cr
because LDH is present in the cytoplasm and is released into the medium when the cell
membrane is compromised. LDH release assays correlate with the 51Cr release assay but
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are less sensitive.8, 343-345
2.6.3.3 Direct cytotoxicity assays: flow cytometry CTL assays
Another commonly used assay to measure CTL response is based on annexin V
binding to apoptotic cells. Upon induction of apoptosis, phoshatidylserine (PS) is
externalized, and so Annexin V will bind to the PS. After effector/target cell incubation,
effector cells are stained with an effector cell-specific antibody, and annexin V–fluorescein
isothiocyanate (FITC) or CFSE is used to stain target cells. To differentiate between early
apoptotic and late apoptotic cells, Propidium Iodide (PI) or 7-amino-actinomycin(7-AAD)
is added. Then the cells are analyzed with a flow cytometer.346, 347
Kim et al., 348 developed a four-color flow cytometry assay that simultaneously
measures effector cell phenotype using K562 or Daudi cells as targets. The targets were
labeled with cell tracker orange prior to the addition of effector cells. After effector/target
cell coincubation, 7-AAD was added followed by phenotypic markers and finally, GrB
antibody. The 7-AAD detected cell death by necrosis and late apoptosis and GrB antibody
detected the presence of proapoptotic activity in targets.
Pickard et al.,290, 349 developed an assay that involves the incubation of target cells
with a GrB substrate. The substrate is designed by inserting a peptide recognition-motif
around the granzyme B cleavage site. Covalent labeling with the same fluorophore at both
ends of the peptide results in quenching. Cleavage of the peptide relieves the quenching,
giving a fluorescent signal. When targets containing the substrate are cocultured with CTL
effectors, the GrB released by effector cells into targets cleaves the substrate to give a
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fluorescent probe that can be detected by a flow cytometer. The presence of this
fluorescence in the cytoplasm of target cells can be used to quantitate and visualize cellular
attack by effector cells.
2.6.4 What to consider before choosing a CTL assay
Before choosing a CTL assay, it’s important to consider the performance
characteristics of the assay and immunological properties of the subjects you are working
with. The assay chosen must have enough sensitivity, specificity, reliability and
reproducibility.309 It must be able to measure T cell response without distorting the
phenotype of effector cells. It is also important that the assay is simple and rapid to perform
and uses a small number of cells. To correctly detect T cell responses, the time points after
vaccination or infection are very important. For each assay, the time point must be chosen
carefully to avoid false negative results since the cells being assayed may have not yet
developed or might have already disappeared from peripheral blood into other lymphoid
organs. Even when the response is at its maximum, but when this maximum response is
below the detection threshold for the assay being used, it will still give a false negative
result. Therefore, it is important to choose an assay that is very sensitive. Finally, the T cell
immune system is very complex so using just one assay or parameter or cell type may not
give a complete analysis of the T cell response, a combination of two or more assays may
give a more realistic evaluation.334
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3.1 Cells

CHAPTER 3. MATERIALS AND METHODS

Equine pulmonary artery endothelial cells (EECs) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Mediatech, Herndon,VA) supplemented with sodium
pyruvate, 10% fetal bovine serum (FBS; HyClone Laboratories,Inc., Logan, UT), 100 U/ml
of penicillin, 100 µg/ml streptomycin, and 200mM L-glutamine. High-passage-number
rabbit kidney cells (HP-RK-13 [KY] P399-409 cells; originally derived from CCL-37 cells
[American Type Culture Collection, Manassas, VA]) were propagated in Eagle’s minimal
essential medium with 10% ferritin-supplemented bovine calf serum (HyClone
Laboratories, Inc., Logan, UT), 100 U/ml of penicillin, and 100 µg/ml of streptomycin
(Gibco, Carlsbad, CA). Primary Equine Dermal Cells (EDCs) were propagated in EDC
growth medium [Eagle’s Minimum Essential Medium (MEM) supplemented with 10%
fetal equine serum (Biowest, Riverside, Missouri USA), 100 U/ml of penicillin and 100
µg/ml streptomycin (Gibco, Carlsbad, CA)]. The EDCs were used as target cells in CTL
assays and as antigen presenting cells in IFN-γ ELISpot assay. Equine Tumor cells
(EQT8888) were obtained from the Animal Health Trust, UK. The EQT8888 cells were
propagated in a mixture of AIM V serum free medium (Thermo Fisher scientific Inc,
Waltham, MA USA) and RPMI 1640 (Gibco,Carlsbad,CA) medium supplemented with
0.05mM non-essential amino acids, 0.5mM sodium pyruvate, 55µM 2- mercaptoethanol,
50µg/ml gentamicin and 10% fetal bovine serum. Lymphokine activated killer (LAK) cells
were generated by incubating PBMCs with 2000Units/ml of recombinant human IL-2
(R&D Systems Inc., Minneapolis MN) for 4 -7 days in RPMI 1640 supplemented with
2.5% fetal equine serum, 55µM 2-mercaptoethanol and 50µg/ml gentamicin.
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3.2 Viruses
Two strains of EAV; the virulent Bucyrus strain (VBS; HP 15 53) and the modified
live virus (MLV) vaccine virus were used in this study. Both viruses were propagated in
EECs to generate high-titer working stocks. EECs infected with each virus were frozen at
-80°C when 90 to 100% cytopathic effect (CPE) was observed. Cell lysates were clarified by
centrifugation (1500 × g) at 4°C for 20 min, followed by ultracentrifugation (Beckman
Coulter, Miami, FL) at 121,600 × g through a 20% sucrose cushion in NET buffer (150
mM NaCl, 5 mM EDTA, 50mMTris-HCl, pH 7.5) at 4°C for 4 h to pellet the virus. Purified
preparations of each strain of EAV were resuspended in phosphate-buffered saline (PBS;
pH 7.4) and frozen at -80°C. Virus stocks were titrated by standard plaque assay in EECs,
and titers were expressed as the number of PFU per milliliter. The VBS strain was UV
inactivated to investigate its use in target cells. 50µL of partially purified EAV VBS was
resuspended in 550µL of Minimum Essential Medium (MEM). 600µl of the virus
suspension was aliquoted onto a 6-well plate and exposed to UV light for 5,10,20,30,60
and 120 seconds using the Spectrolinker XL-1000 (SpectronicsTM Corporation, Westbury
New York). The 6-well plate (without the cover) was placed on wet ice during the exposure
to radiation and a distance of 10cm was maintained between the UV tubes and the bottom
of the plate. An infectivity assay of the TCID50 was set up to determine the degree of UV
inactivation of virus. Flow cytometry analysis for EAV was performed with anti-N (MAb
3E2), anti-GP5 (MAb 6D10) and anti-M (rabbit anti-peptide serum) on primary equine
dermal cells cultured with the UV inactivated virus and live VBS. Virus was also isolated
from semen of three carrier stallions in accordance with the standard protocol used by the
EAV OIE Reference Laboratory at the Maxwell H. Gluck Equine Research Center,
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University of Kentucky.350-352
3.3 Horses
Three confirmed long-term EAV carrier stallions were used in the study. These
were located at the UK North Farm, University of Kentucky, Lexington, KY. Three EAV
seronegative stallions were also included; two of these stallions were vaccinated by the
intramuscular route with the modified live virus (MLV) vaccine (ARVAC). These stallions
were used as a comparison group to the carrier stallion group. Before vaccination, the
stallions were confirmed to be seronegative (<1:4 titer) according to the World
Organization for Animal Health (Office International des Epizooties [OIE]) standardized
protocol.327 Blood was obtained by jugular venipuncture and punch biopsies were collected
from all the six horses. Punch biopsies were used to establish primary equine dermal cell
lines (EDCs) and Peripheral Blood Mononuclear Cells (PBMCs) were isolated from whole
venous blood. Whole venous blood without anticoagulant was also collected for serum
processing. The serum was either used for culture medium supplementation or for serum
neutralization (SNT) and Enzyme-linked immunosorbent assay (ELISA) testing. Blood
was collected at 0, 7, 9, 14, 21, 23, 35, 37, 41, 48, 63, 78, 85- and 99-days post vaccination.
This study was performed in strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National Research Council. The
experimental protocol involving horses was approved by the University of Kentucky
Institutional Animal Care and Use Committee (IACUC; protocol number 2015−1347).
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3.4 Establishment and characterization of primary EDCs
Primary equine dermal cell lines were established for each stallion used in the
study. Skin punch biopsies were collected (under aseptic conditions) from the cervical region
of each horse. The epidermal portion of the skin was removed and immersed into 15ml of
transport medium (500mL of Hank’s Balanced Salt Solution containing 100 IU/ml
penicillin, 10 µg/ml streptomycin, 250µg/ml gentamicin and 2.5mls fungizone). Once at
the laboratory, each biopsy sample was cut into small pieces and transferred into 6 well flatbottomed plates. 22mm round coverslips were gently placed on top of the tissues pieces
before adding warm MEM medium containing 20% fetal equine serum, the plates were
incubated at 37OC, 5% CO2. Growth medium was changed every two days until the cells
formed a confluent layer. The coverslips and the explants were then removed. The cells
were washed with warm Phosphate Buffered Saline (PBS), trypsinized and transferred to
T25 flasks. When flasks were fully confluent, the cells were harvested and resuspended in
freezing medium (10% DMSO in MEM containing 10% fetal bovine serum) at 2 × 106
cells/ml.
Since these primary EDCs were to be used as target cells in a CTL assay, we were
concerned about EAV altering the expression of MHC Class I molecules. So, we obtained
a monoclonal antibody (MAb) against equine MHCI (Clone CZ3) from Dr. Antctzak
(Cornell University) and used it in immunofluorescence staining (IFA) for MHC Class I
expression, we also obtained flow cytometry mouse anti-Equine MHC Class I and Class II
antibodies (clones: 14A2 and H58A) from Washington State University Antibody Centre.
The EDCs were also stained for vimentin, a generic marker for fibroblasts. To determine
the m.o.i of EAV and length of time to infect EDCs, the cells were infected with EAV at
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different m.o.i, at different time points and then Immunofluorescence microscopy (IFA)
was performed. The EDCs were stained with anti-N (MAb 3E2) and anti-nsp1 (MAb
12A4). For flow cytometry, EDCs were cultured in T25 flasks until confluent. One of the
flasks was mock infected while the other flask was infected with EAV VBS at m.o.i of 2
for 24hrs. The cells were harvested by trypsinization and fixed (in the dark) with 3%
paraformaldehyde for 15 min. on wet ice. The cells were centrifuged at 500 × g for 5 min.
and the supernatant removed. The cells were then resuspended in FACS buffer (PBS
containing 1% BSA and 0.1% azide) and 100µL of the cell suspension transferred to a 96
well V-bottom plate. The plate was centrifuged at 500 × g for 5 min. and the cells were
permeabilized with cold 0.1% saponin for 5 min. Blocking was done with 1% Bovine
Serum Albumen (BSA) for 30 min. at room temperature. The cells were washed three times
with FACS buffer. A mouse anti-EAV Nsp1 (MAb 12A4) monoclonal antibody conjugated
to Alexa Fluor 488 was added and the plates incubated on ice for 30 min. After three rounds
of washing, mouse anti-Equine MHC Class I or Class II antibodies conjugated to Alexa
Fluor 647 were added. Thirty thousand live events were acquired on the LRSII flow
cytometer (BD Biosciences, San Jose CA) and data were analyzed with WinList 3D 8.0
(Verity Software House) software.
3.5 Isolation of peripheral blood mononuclear cells (PBMCs) from whole blood
Whole blood was collected via venipuncture into sodium heparin tubes
(Monoject™ Mansfield, MA). The blood was pooled into 50ml conical tubes and
centrifuged at 500 × g for 10 min. The plasma was removed, and the tubes filled with
Hank’s Balanced Salt Solution (HBSS; Thermo Fisher scientific Inc, Waltham, MA USA).
Twenty five mL of the contents of each tube were gently laid onto 20ml of Ficoll
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PaqueTM(Ficoll PaqueTM Plus, GE Healthcare Bio Sciences AB). The tubes were then
centrifuged at 500 ×g for 30 min. at 25O C (with the brake off). The PBMCs at the interface
between the HBSS and the Ficoll were collected into 50ml conical tubes. Forty mL of HBSS
were added and the cell suspensions mixed gently. The tubes were then centrifuged at 500
× g for 10 min. at 250C. The supernatant was removed, and this step repeated twice. The cell
pellet was re-suspended in 10ml of 1X red blood cell lysis buffer (prepared as 10X with
sterile distilled water containing 155mM ammonium chloride, 10mM sodium bicarbonate
and 0.1mM Ethylenediaminetetraacetic acid (EDTA)) and incubated at room temperature
for 5 min. Then 30ml of HBSS were added and tubes were centrifuged as before. The pellet
was resuspended in 10ml of RPMI and cells counted using the Vi-CELL XR instrument
(Beckman Coulter, Brea CA). Some cells were resuspended in freezing medium (10%
DMSO in complete RPMI) while others were saved for in vitro expansion.
3.6 In vitro expansion of in vivo primed effector cells
Since freshly isolated PBMCs contain very few antigen-specific CTLs, there is
need to expand these in vivo stimulated cells using the same virus the horses were infected
or vaccinated with. Therefore, PBMCs (50-100 × 106 cells) from each horse were aliquoted
into two micro-centrifuge tubes. EAV VBS or MLV virus (m. o. i 1) was added to one of
the tubes and the other was mock infected. The tubes were then incubated at 37OC for one
hour. The cell suspensions were later transferred into two separate T75 flasks and 50ml of
induction medium [1:1, v/v, mixture of AIM-V/RPMI 1640 supplemented with 2 mM Lglutamine, 0.5mM minimal essential medium non-essential amino acids, 0.05mM sodium
pyruvate, 55µM 2-mercaptoethanol, 50µg gentamicin and 5% equine serum (collected
from the stallions before vaccination and inactivated at 56OC for 40 min)] were added. The
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PBMCs were incubated at 37OC (upright position), in the presence of 5% CO2 for 7-10 days.
They were later harvested into 50ml tubes, centrifuged at 800 × g for 10 min. and
resuspended in 10ml of complete RPMI (without phenol red) and purified with the ClioCell
dead cell removal kit (AMSBIO, Abingdon UK).
3.7 Cytotoxic T Lymphocyte assays
3.7.1 Granzyme B assay
After in vitro stimulation of PBMCs, a granzyme assay kit (Pan Toxilux;
OncoImmune Gaithersburg, MD) was used in accordance with the manufacturer’s
instructions. Briefly, 2 × 106 of EAV infected or mock infected EDCs were labeled with 1
μL of TFL4 and 1 µL of NFL1 in the dark at RT for 15 min and then washed twice. The
cells were counted and resuspended in wash buffer at a concentration of 1 × 106/ml. Then
100µL of the cell suspension were added to each well of a 96-well round bottomed plate. In
vitro stimulated and mock stimulated PBMCs were resuspended at 5 × 106/ml and 100µL
added to EDCs at different effector/target ratios. 75 μL of PanToxilux substrate (contains
subtrate for granzyme B and upstream caspases) was added to each tube and wash buffer
was added to the controls. The following control wells were included: (1) EDCs target cells
alone; (2) EDCs cells alone with Pan Toxilux substrate (3) Effector cells alone (4) Effector
cells and Pan Toxilux substrate. Each plate was then incubated at 37 °C and 5% CO2 for
60 min, washed twice using wash buffer and re-suspended in 200 μL of wash buffer for
acquisition. Approximately 5000 TL4 positive events were acquired on the BD LSR II.
Data were analyzed with WinList 8.0 software.
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3.7.2 Carboxyfluorescein succinimidyl ester (CFSE) /7-Aminoactinomycin D (7AAD) /Sulforhodamine fluorochrome labeled inhibitor of caspases (SR-FLICA)
assay
The CFSE/7-AAD kit (Abcam, Cambridge MA) was used in this assay. To prepare
target cells, two T25 flasks of EDCs were used; one flask was infected with 2 m.o.i of EAV
VBS and the other was mock infected for 8h at 37oC in the presence of 5% CO2. The targets
were harvested onto 15ml tubes, washed once with PBS and resuspended in CFSE at 1×106
cells/ml for 15 min. at room temperature. After staining with CFSE, targets were
resuspended in MEM (containing 10% fetal equine serum) and diluted to 4 × 105 cells/ml.
100µl of this cell suspension was aliquoted into each well of the 96-well round-bottom
plate. Effector cells were prepared as described above and then added to the target cells at
different Effector (E): Target (T) ratios. The plates were incubated at 37OC, 5% CO2 for 4h.
CTL activity was detected by adding SR-FLICA dye to the cells and incubating them at
37OC, 5% CO2 for 1h. This reagent recognizes and binds to active caspases in target cells.
It is a marker for apoptotic cells in this assay. To differentiate between necrotic and
apoptotic cells, 7-AAD was added and the cells incubated at 4OC for 15 min. Using a CFSE
versus side scatter plot, 3000 CFSE+ events were acquired on the iCyt Synergy flow
ytometer. Data were analyzed with WinList 3D 8.0 software.
3.7.3 Lactate dehydrogenase (LDH) assay
Initially, the LDH assay was performed with Lymphokine Activated Killer (LAK)
cells as effector cells and EQT8888 cells as target cells. LAK cells were generated as
describe by Liu et al.,353 and Hormanski et al.,354 PBMCs prepared as described above were
re- suspended at a concentration of 1.0 × 106 cells/ml in 10ml of RPMI-1640 (Gibco, Grand
Island, NY) supplemented with 2.5% (v/v) fetal equine serum, 2 mM glutamine (Sigma),
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50µg/ml gentamicin, and 55μM 2-mercaptoethanol (GIBCO, Grand Island, NY). The
PBMC were incubated (at 37 °C in 5% CO2) for 4-8 days in T25 flasks supplemented with
2000U/ml of recombinant human interleukin 2 (hIL-2; R&D Systems, Minneapolis, MN)
to generate LAK cells. The LAK cells were harvested, resuspended in RPMI 1640 (with no
phenol red) and counted with the Vi-CELL XR instrument (Beckman Coulter, Miami FL).
The cells were then purified by means of ClioCell dead cell removal kit (AMSBIO,
Abingdon UK) to remove dead cells. EQT8888 cells were cultured for 24h before the LDH
assay was performed. These cells were re-suspended at a concentration of 3 × 105 cells/ml in
RPMI 1640 (with no phenol red). 50µL of this cell suspension was aliquoted into each well
of a 96-well round-bottom plate except for control wells. 50µL of LAK cells was then
added at different E:T ratios and the plates incubated at 37oC in the presence of 5% CO2
for 6h. After incubation, plates were centrifuged at 250 × g for 3 min. The supernatants
were collected and transferred to a 96-well flat-bottomed plate. 50µL of the LDH substrate
(Pierce LDH cytotoxicity assay kit; Rockfold, IL) was added to each well and the plates
incubated at room temperature for 30 min. The reaction was stopped by adding 50µL of
the stop solution. Absorbance was measured at 490nm and 680nm with a
spectrophotometer (BioTek synergy H1 hybrid; Winooski, Vermont).
After optimizing the LDH assay with LAK cells, the above described procedure
was then repeated with EDCs as targets and in vitro stimulated PBMCs as effector cells.
In this approach, EDC targets for each stallion were cultured in T25 flasks until confluent.
Each T25 flask contained approximately 2.5 × 106 cells. The cells were trypsinized and
resuspended in EDC growth medium (with no phenol red) at a concentration of 3 x 105/ml,
50µL of this cell suspension was transferred per well of a 96-well except for control wells.
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The plates were incubated at 37OC in the presence of 5% CO2 for 12h to allow the cells to
adhere to the plates. The medium was removed and 100µL of EDC growth medium
containing 5% fetal equine serum with or without 10 m.o.i virus were added to the
appropriate wells and the plated incubated for another 8h before adding effector cells. The
medium was removed, and the plates were washed three times with 300µL of warm sterile
PBS (pH 7.0). 50µL of effector cell suspension were added at different E:T ratios in
triplicates and the plates were incubated at 37OC in the presence of 5% CO2 for 6h.
For both scenarios, maximal target cells lysis was achieved by adding 10µL of 10x
lysis buffer to triplicate wells containing target cells only. Four groups of controls were
also set up: 1) Medium only; 2) Target cells only (target minimum); 3) Effector cells only
for each E:T ratio; 4) Volume correction. Percent cytotoxicity was calculated using the
following formula;

%𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 =

𝑂𝑂𝑂𝑂 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 − 𝑂𝑂𝑂𝑂 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 − 𝑂𝑂𝑂𝑂 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑂𝑂𝑂𝑂 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 − 𝑂𝑂𝑂𝑂 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚
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3.8 Transfection of EDCs with EAV RNA(IVTRNA)
In vitro transcribed RNA was generated for EAV GP5/M, GP5, M and N using the
RiboMax large scale RNA production system (Promega, Madison WI). As a control, blue
tongue virus (BTV) M5 was also included. E. coli cells were transformed with plasmids
carrying the above ORFs and the cells plated on LB agar overnight. A single colony was
picked and inoculated into 250ml of LB broth and the flasks placed in the incubator shaker
overnight. The following day, the plasmids were purified using the QIAgen maxiprep kit
(QIAgen, Carlsbad,CA). The plasmids were then linearized using NotI restriction enzyme
before chloroform extraction. In vitro transcribed RNA was synthesized using the RiboMax
kit from Promega following the manufacturer’s instructions. Ten microliters of the IVT
RNA was aliquoted into tubes and stored at -800C. Three microliters from each tube was
used for transfection with the LONZA SE 4D transfection kit. Immunofluorescence
microscopy was then carried out to confirm that transfection had taken place.
3.9 Interferon-gamma enzyme-linked immune absorbent spot (IFN-γ ELISpot)
assay
A crude overlapping peptide library was synthesized (GenScript, Piscataway, NJ)
from open reading frame 7 (of the MLV vaccine strain) which encodes N protein. The
peptides were 15aa long and overlapped by 11aa. The peptides were dissolved in 50µL of
dimethylsuilfoxide (DMSO) and 950µL of distilled water were added to each tube, aliquots
of each peptide were made and stored at -80OC. The ELISPOT assay was performed with
EDCs transfected with M, N, GP5 and GP5/M of EAV. The equine IFN-γ ELISpot kits
were obtained from Mabtech (Mabtech,Cincinnati,OH) and used in accordance with the
manufacturer’s instructions.

49

To perform the assay, 3 tubes of PBMCs for each horse were removed from the
freezer. They were immediately thawed (in a water bath) and the cells resuspended in 25ml
of RPMI containing 20% fetal bovine serum. The tubes were then transferred to an
incubator for 10h. The following day, the cells were centrifuged at 500 × g for 10 min. and
resuspended into 10ml of complete RPMI containing 2% horse serum and counted. Cell
viability was >85%. For transfected EDCs, the cells were placed into an ELISpot plate at
approximately 20 X 104 cells/well and 2.5 x 105 PBMCs/well were added. For peptides,
50µg/ml or 100µg/ml of each peptide in different peptide pools was added per well.
PMA/Ionomycin was added to the positive control wells. The plates were wrapped in
aluminum foil and incubated at 37OC for 20h. Live EAV VBS and MLV virus were used in
the ELISpot assay at 1 m.o.i. Each virus was mixed with PBMCs and incubated at 37OC for
1 hour before adding the cells to the ELISpot plates. The number of spots was enumerated
by the CTL ELISPOT reader. The number of spots in the medium only was subtracted from
the number spots in each of the test sample.
3.10 Virus neutralization (VN) test
Antibody determination was conducted with the virus neutralization (VN) test as
described in the OIE Manual for Diagnostics and Vaccines for Terrestrial Animals.76, 352 A
total of 16 stallions were screened for EAV neutralizing antibodies to identify the horses to
be vaccinated. Stallions that were less than 20 years of age and had a titer of < 1:4 were
included in the study. The ELISpot assay was performed on the selected stallions to identify
those stallions whose PBMCs had low levels of spontaneous IFN-γ release.
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CHAPTER 4. RESULTS
4.1 Virus neutralization (VN) test
The outcome of VN testing of the sera from 16 horses for EAV antibodies before
vaccination is presented in Table 1. After vaccination with the MLV vaccine, serum was
collected at the time points shown in Table 2 to determine whether the horses had
seroconverted or not. Serum was also collected from the three carrier stallions to establish
their infective VN titers for EAV (Table 3). All vaccinated horses seroconverted by day
14 post vaccination. They all had a titre of 1:512 by day 23.
Table 1: Results of screening stallions for VN antibodies to EAV
Horse ID

Sex

Breed

Age (Years)

VN antibody titre

1

K113

Stallion

QH

18

1:256

2

L111

Stallion

Pony

24

1:256

3

L118

Stallion

Pony

ND

<1:4

4

L134

Stallion

TB

9

<1:4

5

N118

Stallion

Paint

7

<1:4

6

N120

Stallion

app

21

<1:4

7

N122

Stallion

TWHX

8

<1:4

8

N123

Stallion

QHX

14

<1:4

9

O114

Stallion

TWHX

13

<1:4

10

O121

Stallion

TB

4

<1:4

11

636

Mare

STB

21

<1:4

12

641

Mare

Arab

ND

<1:4

13

B008

Mare

STBX

15

<1:4

14

B083

Mare

QH

ND

<1:4

15

G011

Mare

TB

10

1:128

16

C067

Mare

TB

14

<1:4

ND – Not determined
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Table 2: EAV VN antibody findings at different time-points after vaccination
Days post vaccination

Treatment group

VN antibody titre

Unvaccinated
Vaccinated
Vaccinated
Carrier stallion
Known seronegative horse

Day 0
Horse ID
O114
L134
N122
H069
O121

< 1:4
<1:4
<1:4
> 512
< 1:4

Unvaccinated
Vaccinated
Vaccinated
Carrier stallion
Known seronegative horse

Day 14
Horse ID
O114
L134
N122
H069
O121

< 1:4
1:256
1:128
> 512
< 1:4

Unvaccinated
Vaccinated
Vaccinated
Carrier stallion
Known seronegative horse

Day 23
Horse ID
O114
L134
N122
H069
O121

< 1:4
1:512
> 512
> 512
< 1:4

Unvaccinated
Vaccinated
Vaccinated
Carrier stallion
Known seronegative horse

Day 37
Horse ID
O114
L134
N122
H069
O121

< 1:4
> 512
> 512
> 512
< 1:4

Unvaccinated
Vaccinated
Vaccinated
Carrier stallion
Known seronegative horse

Day 41
Horse ID
O114
L134
N122
H069
O121

< 1:4
> 512
> 512
> 512
< 1:4

Table 3: Virus neutralization test and competitive ELISA (cELISA) results for EAV in
three carrier stallions
Horse ID
I050
I070
H069

Horse Breed
Rocky Mountain
Tennessee Walker
Paint

VN Titers
1:256
1:512
>1:512

52

VN
+
+
+

cELISA

+
+
+

4.2 Establishment and characterization of primary EDCs
EDCs for stallion H069 were mock and EAV infected. Expression of MHC class I
and class II was detected by IFA (Figure 5) and flow cytometry (Figure 6). The EDCs were
also tested for expression of EAV NspI (Figure 6).

Figure 5: Immunofluorescence microscopy performed on primary EDCs.
A) Primary EDCs stained with mouse anti-Equine MHC Class I antibody;
B) Primary EDCs stained with mouse anti-human vimentin antibody;
C) Secondary antibody alone (anti-mouse Alexa Fluor 488)
Data from IFA and flow cytometry (Figure 5 & Figure 6) show that EDCs constitutively
express high levels of MHCI but not MHCII. EDCs were also susceptible to EAV since
expression of nspI was detected in EDCs treated with EAV.

Figure 6: Flow cytometry data for expression of MHC class I and MHC class II
molecules on Mock infected and EAV infected primary equine dermal cells (EDCs).
EDCs were infected (at 2 m. o. i) with EAV VBS for 24hrs.
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To determine the optimal m.o.i of virus and length of time to infect, IFA was
conducted on EDCs infected with different m.o.i of EAV at different time points. At 8h and
12h, the nsp1 protein is mainly localized to the nucleus (Figure 7) but at 24 hours it is
predominant in the cytoplasm. The M protein is mainly expressed in the cytoplasm at all
time points studied (Figure 8). From these data it is evident that 2 m. o. i for 24hrs would
work well for T cell assays.

Figure 7: Immunofluorescence staining of EDCs infected with EAV VBS and stained
with primary antibody mouse anti-nsp1 and secondary antibody anti-mouse Alexa Fluor
488

Figure 8: Immunofluorescence staining of EDCs infected with EAV VBS and stained
with primary antibody mouse anti-M and secondary antibody anti-mouse Alexa Fluor 594
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4.3 Ultraviolet (UV) inactivation of EAV VBS
EAV VBS was UV inactivated to determine if it can be used in CTL assays instead
of live virus. Since the CTL assays used in this study rely on target cell lysis induced by
the granzyme B pathway, and EAV is known to induce apoptosis, using live virus would
create high background.

Figure 9: UV inactivation of EAV VBS. Red bars show virus titers for live virus
while the blue bars show virus titers for UV inactivated virus. These data clearly
demonstrate that EAV is rapidly inactivated by UV light
However, the data in figure 10 indicate that UV inactivated virus is not able to infect
EDCs since there was no staining of viral proteins as per flow cytometry data (Figure 10).
Data from figure 9 shows that the virus is completely inactivated as early as 2 minutes of
exposure to UV light (Figure 9).

Figure 10: Flow cytometry analysis of EDCs infected with live and UV inactivated EAV
VBS
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4.4 Interferon-gamma ELISpot Assay (IFN-γ ELISpot) performed with
transfected EDCs
Currently, it’s not possible to predict ELA epitopes using available epitope prediction
software. To go around this problem, we performed transient transfection (of EDCs) with
EAV viral proteins to produce full length proteins that would probably contain anchor
amino acids for ELA of all the horses used in this study.

Figure 11: IFA staining of EDCs transfected with EAV IVT RNA (24h transfection)
Immunofluorescence microscopy data indicates that transfected EDCs express high
levels of viral proteins at 24h post transfection which drops tremendous by 48hrs (data not
shown). So, for the IFN-γ ELISpot assay, the 24h time point was used (Figure 11).

Figure 12: ELISpot data conducted with PBMCs (isolated from carrier stallions)
stimulated with autologous EDCs transfected with EAV IVT RNA
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Stimulation of PBMCs with transfected EDCs seemed to produce positive results (Figure
12), but this response could not be reproduced with peptide pools or virus.
4.5 Measuring cytotoxicity of in vitro stimulated PBMCs with the LDH assay
Cell mediated response against EAV was measured using PBMCs from vaccinated
stallions (n=2), long term carrier stallions (n=3) and one EAV seronegative stallion. The
PBMCs were incubated in vitro with or without virus for 7-10 days. The PBMCs were later
co-cultured with EDCs that had been mock infected or infected with EAV VBS or MLV
virus.

Figure 13: Results of LDH assays performed with LAK cells and EQT8888 cells at
different E:T ratios. A) Low E:T ratios B) High E:T ratios
The LDH assay was first optimized with LAK cells and EQT8888 cells. LAK cells
were cocultured with EQT8888 cells at 37OC in the presence of 5% CO2 for 6h at different
E:T ratios. A range of E:T ratios was tried, and it was very clear that this assay works well
at low E:T ratios (Figure 13). As the E:T ratio increased, so did the number of dead or
dying cells thus lowering the signal/noise ratio and leading to reduced or no target lysis
signal. After optimizing the LDH assay with LAK cells, the assay was applied to PBMCs
isolated from long-term carrier stallions (Figure 14) and vaccinated stallions. Positive data
was only observed in one vaccinated stallion (at day 99) and this was obtained after in vitro
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re-stimulation of PBMCs with the MLV virus for 10 days (Figure 15).

Figure 14: LDH data for carrier stallions
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Figure 15: LDH data for vaccinated horses (N122 and L134) and one naïve horse (0114)

CHAPTER 5. DISCUSSION AND CONCLUSION
5.1 Discussion
In this study, four assays were evaluated for monitoring T cell immunity in EAV
infected horses. The flow cytometric assays work well with nonadherent target cells, they
have been evaluated in this context and found to be more sensitive and more informative
than the chromium release assay.355, 356 Since EDCs are adherent cells, it was not possible
to optimize these assays. Flow cytometry assays also require immediate analysis to
minimize background emanating from dying cells.357 This requires that the laboratory have
a flow cytometer on-site. For these reasons, we only evaluated the LDH and ELISpot
assays.
The data from the ELISpot assay was inconsistent as transfected cells provided
some positive results, but peptides and EAV did not. Since frozen PBMCs were used for
all ELISpot assays, this could be the reason why peptide and virus stimulated PBMCs did
not respond. Very low numbers of monocytes have been reported in frozen PBMCs which is
consistent with our findings. In this study, frozen PBMCs were tested for CD14 expression
and monocytes could not be detected (data not shown), they were neither seen on the side
scatter vs forward scatter plot. This is supported by the study of Castillo-Olivares et al. 260
who failed to detect a CTL response using frozen PBMCs in their 51Cr release assay. They
also noted that frozen PBMCs were not susceptible to EAV as expression of N protein was
not detected in frozen PBMCs exposed to EAV.
The data obtained using EDCs could also be non-specific since blue tongue virus
(BTV) M5 transfected EDCs also showed high spot forming units in stallion I050. The
carrier stallions used in this study are over 30 years old, and old horses tend to have
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spontaneous production of IFN-γ. It should also be noted that EDCs do not express MHCII antigens, thus are unable to stimulate a CD4+ T cell response. This would result in a lack
of “help” for the CD8+ T cells. While other APC in the PBMC culture could present antigen
to CD4+ T cells. Equine dermal cells may also lack some of the costimulatory molecules
expressed by professional antigen presenting cells. Thus, will fail to stimulate T cell
proliferation and cytokine production if exogenous cytokines are not added to the culture
medium.358 Since electroporated EDCs tend to clump, it is very difficult to add an equal
number of cells per well; this will result in a lot of variation in number of spots between
wells. Equine dermal cells are adherent cells, using them in the ELISpot plate not only
introduced artefacts, but it also interfered with the detection antibody binding thus creating
a lot of background. Non-adherent cells like dendritic cells are better suited for this kind of
analysis.
In mouse models, T cell function is measured using cells obtained from lymphoid
tissues such as spleen, bone marrow and lymph nodes. These tissues have a high
concentration of antigen specific T cells so do not require in vitro re-stimulation for several
days. PBMCs, on the other hand, require in vitro stimulation for 7-21 days. This process
can have profound modifying effect on T cell function. Besides, cultured cells tend to have
high numbers of dead or dying cells, which can be a source of high background in most
CTL assays. The LDH assay has the same working principle as
differs from the
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Cr release assay but

Cr release assay in that it relies on the intrinsic cellular production of

lactate dehydrogenase. Its sensitivity is highly affected by high background coming from
culturing cells for several days. Consequently, high E: T ratios are not recommended as
these will lead to very low signal/noise ratios (Figure 13B). Since PBMCs contain low
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concentrations of antigen specific cells, low E:T ratios might under-estimate or fail to
capture antigen specific T cell responses especially when they are below the detection
threshold of the assay. This could be the reason why we were not able to detect CTL lysis
in PBMCs stimulated for 7 days. Even with effectors stimulated for 10 days, only one
stallion of the two vaccinated stallions responded. Carrier stallions did not show any CTL
response at 7 and 10 days of EAV in vitro re-stimulation. Several reasons could account
for this: 1) the strain of EAV used for re-stimulation is a laboratory adapted strain and
could lack the epitopes recognized by the CTLs of carrier stallions ; 2) since these horses
have been shedding virus in semen for over ten years, EAV specific CTLs could be
sequestered in the reproductive tract and not present in the peripheral circulation; 3) the
CTL response could have diminished with time and so not detectable.
Finally, 99 days after vaccination may not be an optimal time to evaluate the LDH
assay because the cellular immune response to EAV may not be properly developed and
thus could be below the threshold for LDH assay detection given that this assay is not very
sensitive. This is supported by the observation of Castillo-Olivares et al.,260 who were
unable to detect a CTL response before 4 months of infection. This raises the need to further
validate this assay with a larger number of vaccinated horses and allow enough time for
the immune system to develop before using the LDH assay to measure CTL response.
Another approach could be to look at other CTL assays that are more sensitive and specific.
One such assay is the granzyme B ELISpot assay which is simple, rapid, very sensitive,
reproducible and does not use a lot of cells. The other very sensitive and robust assay is
tetramer assay, tetramers have been developed for equine leucocyte antigen A1(ELAA1).298 The same approach could be used to produce EAV peptide tetramers to avoid the
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problems associated with culturing effector cells for days and using assays with low
sensitivity.
5.2 Conclusion
The LDH assay discussed in this study works well with cells obtained from
lymphoid organs. Because of the reasons discussed above, I wouldn’t recommend it to
someone working with PBMCs. In my opinion, equine T cell research should stick with
the chromium release assay until a new validated and sensitive assay is introduced e.g. the
tetramer, granzyme B ELISpot or TCR phenotyping. Also, the process of choosing horses to
include in any T cell study should ensure that the most common ELA haplotypes are
properly represented in both the control group and test group. This will improve the
probability of identifying epitopes, and there will be no need to use transfected cells as
antigen presenting cells.
Because of the reasons mentioned above, naturally infected long-term EAV carrier
stallions are a poor model to study T cell immunity to EAV. Unless the stallions are infected
with a known EAV strain and followed overtime, there will always be problems working
with naturally infected long-term carrier stallions. This is because, the infecting EAV virus
is not always known and so will require isolation of the virus, sequencing it and making
peptides out of each isolate which is costly and time consuming. Isolation of the virus from
semen and using it in the ELISpot assay will still give high background since semen
contains bacteria that produce endotoxins. Furthermore, EAV semen isolates cannot be
used for in vitro re-stimulation because the viruses are not culture adapted so most of them
will not infect PBMCs. Therefore, T cell studies require cautious planning before any
experiments can commence.
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